Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD4054 versus placebo in hormone-resistant prostate cancer with bone metastases
NL-OMON31111Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing ZD4054 10 mg with Placebo (2 arms). Primary endpoint: Overall survival. Started Oct 2007; status: active, not recruiting.
02
Drugs
zibotentan
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON31111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31111.